Diabetic Macular Edema Pipeline Review 2021

Diabetic Macular Edema- Pipeline Review

Macular edema is aggregation of fluid in the macula. Macula is an area in the center of the retina. The retina is located at the back of the eye and is light-sensitive tissue. The macula is the part of the retina accounted for sharp, straight-ahead vision. The fluid which is aggregated into macula causes it to swell and thicken, which distorts vision. The primary indication of macular edema is wavy or blurry vision near or in the center of our field of vision. Another symptoms may be washed out or faded appearance of color. Most people suffering from macular edema will have indications that range from slightly blurry vision to noticeable vision loss.

According to data published by National Eye Institute, around 7.7 million Americans have diabetic retinopathy and out of those about 750,000 also have DME. The current study reports that non-Hispanic African Americans are three times more likely to develop DME than non-Hispanic whites. This is attributed mainly due to the growing incidence of diabetes in the African American population.

In recent years, Pharmaceutical companies have targeted several therapies combinations, towards different pathways for the treatment of DME. Various conventional treatments are aimed at sustaining the patient’s vision and decreasing future vision loss through medication and laser surgery. Boehringer Ingelheim and pharmaceutical research company Pharmaxis declared that Boehringer Ingelheim has introduced the Phase IIa study ROBIN (Randomized study of orally administered BI 1467335 in patients suffering from Non-proliferative diabetic retinopathy without center-involved diabetic macular edema).

Approximately 70% of pipeline drugs for Diabetic Macular Edema are in phase 2 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent Diabetic Macular Edema.

Report Description

The report on Diabetic Macular Edema- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for Diabetic Macular Edema. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

• Assessment of pipeline products based on various stages of devolvement.
• Provides an overview of the global therapeutic landscape of Diabetic Macular Edema (Infectious Disease).
• Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
• The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
• Latest news, articles, press-release, and related conferences

• Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies
• Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
• Build strategic initiatives by understanding the focus areas of leading companies
• Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline